Author: Admin

AVROBIO, Inc. Announces Acceptance of Investigational New Drug (IND) Application for Investigator-Sponsored Phase 1/2 Clinical Trial for AVR-RD-04 Gene Therapy for Cystinosis

From Startup Avrobio Link to Full Article: Phase 1/2 study to be led by team at University of California, San Diego, with rights licensed to AVROBIO CAMBRIDGE, Mass., Jan. 18, 2019 (GLOBE NEWSWIRE) — AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”) a Phase 2 clinical-stage gene therapy company, today announced that

AVROBIO, Inc. Announces Analyst and Investor Event and Upcoming Clinical Data Presentations at WORLDSymposium 2019

From Startup Avrobio Link to Full Article: Analyst and Investor Event to be Webcast on Wednesday, February 6, 2019 at 6:30 p.m. ET CAMBRIDGE, Mass., Jan. 17, 2019 (GLOBE NEWSWIRE) — AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced that clinical trial updates

Anika Announces Plans to Showcase HYALOFAST at the International Cartilage Regeneration and Joint Preservation Society (ICRS) Summit in San Diego

From Startup Anika Therapeutics Link to Full Article: BEDFORD, Mass.–(BUSINESS WIRE)–Jan. 16, 2019– Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced plans to showcase HYALOFAST, a biodegradable, HA-based cartilage repair scaffold,

Precision BioSciences Announces Formation of Scientific Advisory Board With Anderson, Kantarjian, Schinazi and Turtle

From Startup Precision Biosciences Link to Full Article: DURHAM, North Carolina, USA, January 16, 2019 – Precision BioSciences today announced the formation of its Scientific Advisory Board (SAB) with four key appointments: Kenneth C. Anderson, MD, Hagop Kantarjian, MD, Raymond Schinazi, PhD, DSc, and Cameron Turtle, MBBS, PhD. Drs. Anderson, Kantarjian,

Science Translational Medicine Publishes First-in-Human Clinical Data and Supporting Preclinical Data for SYNB1020, Synlogic’s Synthetic Biotic™ Medicine in Development as a Potential Treatment for Hyperammonemia

From Startup Synlogic Tx Link to Full Article: –Phase 1 clinical trial to evaluate safety and tolerability of SYNB1020 in healthy volunteers demonstrated safety, clearance and proof of mechanism– – Data from ongoing Phase 1b/2a clinical trial in patients with cirrhosis and elevated ammonia expected mid-2019 – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan.

Aptinyx Reports Top-line Results from Phase 2 Clinical Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy

From Startup Aptinyx Link to Full Article: NYX-2925 did not achieve statistically significant separation from placebo on primary endpoint Meaningful improvements on pain and other endpoints observed in subjects receiving 50 mg dose and in subjects not taking a concomitant analgesic medication NYX-2925 was well-tolerated with no significant adverse

BrainStorm to Present NurOwn® Phase 3 Study Update at the 9th Annual California ALS Research Summit in Irvine, CA

From Startup Brainstorm Cell Therapeutics Link to Full Article: Dr. Ralph Kern to Provide Update on the Phase 3 Pivotal Trial of Autologous MSC-NTF Cellular Therapy (NurOwn®) in ALS   NEW YORK and IRVINE, Calif., Jan. 11, 2019 (GLOBE NEWSWIRE) — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in

Led by Philips, Prenatal App Babyscripts Nabs $6M to Support Holistic Care for Mothers

From Startup BabyScripts Link to Full Article: Babyscripts, Inc., a Washington D.C.-based virtual care platform for managing obstetrics, announced today that Philips has taken a minority position in the company by leading a $6 million round of financing. The round also included participation from investors StartUp Health and NueCura Partners.